VERO vs SSKN vs INMD vs DERM

For growth investors, STRATA Skin Sciences, Inc.

(SSKN) is the stronger pick with 0. 6% revenue growth year-over-year, versus -29. 1% for Journey Medical Corporation (DERM). InMode Ltd. (INMD) offers the better valuation at 9. 7x trailing P/E (9. 6x forward), making it the more compelling value choice. Analysts rate InMode Ltd. (INMD) a "Buy" — based on 11 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, InMode Ltd.

is actually cheaper at 9. 6x.

Over the past 5 years, Journey Medical Corporation (DERM) delivered a total return of -47.

4%, compared to -99. 9% for Venus Concept Inc. (VERO). Over 10 years, the gap is even starker: INMD returned +105. 0% versus VERO's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), STRATA Skin Sciences, Inc.

(SSKN) is the lower-risk stock at -0. 24β versus Journey Medical Corporation's 1. 82β — meaning DERM is approximately -844% more volatile than SSKN relative to the S&P 500. On balance sheet safety, InMode Ltd. (INMD) carries a lower debt/equity ratio of 2% versus 15% for Venus Concept Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), STRATA Skin Sciences, Inc.

(SSKN) is pulling ahead at 0. 6% versus -29. 1% for Journey Medical Corporation (DERM). On earnings-per-share growth, the picture is similar: STRATA Skin Sciences, Inc. grew EPS 16. 1% year-over-year, compared to -869. 0% for Venus Concept Inc.. Over a 3-year CAGR, SSKN leads at 3. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

InMode Ltd.

(INMD) is the more profitable company, earning 25. 3% net margin versus -72. 5% for Venus Concept Inc. — meaning it keeps 25. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: INMD leads at 23. 0% versus -41. 9% for VERO. At the gross margin level — before operating expenses — INMD leads at 78. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, InMode Ltd.

(INMD) trades at 9. 6x forward P/E versus 69. 0x for Journey Medical Corporation — 59. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for DERM: 135. 0% to $11. 75.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, STRATA Skin Sciences, Inc.

(SSKN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0. 24)). Journey Medical Corporation (DERM) carries a higher beta of 1. 82 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (SSKN: -99. 6%, DERM: -47. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: VERO is a small-cap quality compounder stock; SSKN is a small-cap quality compounder stock; INMD is a small-cap deep-value stock; DERM is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.